Artemis Therapeutics Inc.
ATMS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $176 | $206 | $173 | $116 |
| % Growth | -14.6% | 19.1% | 49.1% | – |
| Cost of Goods Sold | $9 | $13 | $29 | $29 |
| Gross Profit | $167 | $193 | $144 | $87 |
| % Margin | 94.9% | 93.7% | 83.2% | 75% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $204 | $244 | $213 | $456 |
| SG&A Expenses | $320 | $466 | $408 | $964 |
| Sales & Mktg Exp. | $116 | $222 | $195 | $199 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $320 | $466 | $408 | $581 |
| Operating Income | -$153 | -$273 | -$264 | -$494 |
| % Margin | -86.9% | -132.5% | -152.6% | -425.9% |
| Other Income/Exp. Net | $0 | $288 | $15 | -$12 |
| Pre-Tax Income | $0 | $15 | -$249 | -$506 |
| Tax Expense | $0 | $0 | -$15 | $12 |
| Net Income | $0 | $15 | -$234 | -$518 |
| % Margin | 0% | 7.3% | -135.3% | -446.6% |
| EPS | 0 | 0 | -0.002 | -0.091 |
| % Growth | -100% | 100% | 97.7% | – |
| EPS Diluted | 0 | 0 | -0.002 | -0.091 |
| Weighted Avg Shares Out | 112,033,909 | 112,033,909 | 112,034 | 5,706 |
| Weighted Avg Shares Out Dil | 112,033,909 | 112,033,909 | 112,034 | 5,706 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | -$15 | $12 |
| Depreciation & Amortization | -$40 | $122 | $4 | -$65 |
| EBITDA | -$153 | -$273 | -$260 | -$490 |
| % Margin | -86.9% | -132.5% | -150.3% | -422.4% |